Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info

A look at the status of suits involving Remicade, Neulasta, Epogen and Enbrel proposed biosimilars; Humira patents are being challenged in inter partes review proceedings rather than district court.

Gavel_1200x675

Past performance does not predict future returns in the stock market – or in biosimilar litigation. Pfizer Inc. agreed to Janssen Biotech Inc.'s demand that it not launch Inflectra, a biosimilar to Remicade (infliximab), before Oct. 3. It did so immediately after the U.S. Court of Appeals for the Federal Circuit ruled that 180-day notice of commercial marketing is required after licensure whether or not a biosimilar sponsor has engaged in the patent information exchange process laid out in the biosimilar statute.

But Pfizer is not taking such a conciliatory position in litigation over its biosimilar to Amgen Inc.'s Epogen (epoietin alfa). In that case, Pfizer argues that the Federal Circuit's decision in Amgen v. Apotex Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Pink Sheet